Research Article Details
| Article ID: | A23511 |
| PMID: | 25755484 |
| Source: | J Clin Exp Hepatol |
| Title: | The future liver of the Asia pacific: fatter and firmer from more fructose and fortune? |
| Abstract: | The Asia Pacific region is the most diverse and the most populous region in the world. Recent socioeconomic changes have resulted in an emerging epidemic of non-communicable diseases such as type 2 diabetes and nonalcoholic fatty liver disease. The prevalence of nonalcoholic fatty liver disease in Asian Pacific countries now approximates that seen in Western countries. This increase is fueled by rising obesity, partly due to adoption of Western style diets and exposure to compounds such as high fructose corn syrup that are not included in traditional diets. Furthermore, South Asian populations may be more genetically susceptible via the inheritance of polymorphisms in apolipoprotein 3 that increase insulin resistance and nonalcoholic fatty liver disease. Importantly, there remains a substantial lack of data on the incidence and natural history of nonalcoholic steatohepatitis and subsequent complications such as hepatocellular carcinoma in Asian Pacific populations. This information gap prevents estimation of current and future disease burden and impedes efforts to lobby health policymakers to improve public health measures, as given the size of Asian Pacific populations, prevention rather than treatment of non-communicable diseases remains key. This review article addresses these issues and highlights research priorities for nonalcoholic fatty liver disease within the Asia Pacific region. |
| DOI: | 10.1016/j.jceh.2012.10.011 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D142 | Fructose | Chemical drug | DB04173 | -- | Intravenous nutrition drug | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |